Application of antibiotic-loaded bone cement in unicompartmental knee arthroplasty: inhibiting IL-6 levels and reducing postoperative infection rate.

IF 3.1 4区医学 Q3 IMMUNOLOGY

Immunopharmacology and Immunotoxicology Pub Date : 2026-10-10 DOI:10.1080/08923973.2026.2725838

Dexiang Zhang, Yang Shen, Shaobing Zhang, Xiaolong Xiong

{"title":"Application of antibiotic-loaded bone cement in unicompartmental knee arthroplasty: inhibiting IL-6 levels and reducing postoperative infection rate.","authors":"Dexiang Zhang, Yang Shen, Shaobing Zhang, Xiaolong Xiong","doi":"10.1080/08923973.2026.2725838","DOIUrl":null,"url":null,"abstract":"Objective: We aim to clarify the inhibitory effect of antibiotic-loaded bone cement (ALBC) on inflammatory factors, and its preventive effect on postoperative infections in unicompartmental knee arthroplasty (UKA).Methods: This prospective randomized controlled trial enrolled 104 osteoarthritis patients undergoing UKA, randomly assigned to the non-ALBC group (n = 52, bone cement without antibiotics) and ALBC group (ALBC with 1.0 g vancomycin hydrochloride, n = 52). Primary outcomes were postoperative inflammatory markers (CRP, ESR, TNF-α, IL-6); secondary outcomes included infection rate and HSS score. Independent-samples t-tests were used for continuous variables, χ2 test for categorical variables (infection rate, efficacy), and repeated measures analysis of variance for intra-group longitudinal comparisons.Results: The ALBC group demonstrated lower inflammatory markers at postoperative day 7 and at 3 months [CRP (3.52 ± 0.81 vs 6.92 ± 1.17, Cohen's d = 3.379), ESR (16.29 ± 2.31 vs 20.19 ± 4.05, Cohen's d = 1.183), TNF-α (29.71 ± 4.03 vs 36.25 ± 5.17, Cohen's d = 1.411), and IL-6 (17.05 ± 3.72 vs 22.05 ± 4.38, Cohen's d = 1.230)] (all p < 0.001), and also showed superior clinical outcomes, with lower postoperative infection rate (p = 0.016), higher HSS score (p < 0.001), and better overall clinical efficacy (p = 0.010) than the non-ALBC group.Conclusion: The application of ALBC in UKA was associated with reduced postoperative inflammatory markers such as IL-6 and a lower incidence of postoperative infection. These findings suggest that ALBC may play a beneficial role in postoperative recovery and joint function rehabilitation.","PeriodicalId":13420,"journal":{"name":"Immunopharmacology and Immunotoxicology","volume":" ","pages":"1-8"},"PeriodicalIF":3.1000,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopharmacology and Immunotoxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08923973.2026.2725838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aim to clarify the inhibitory effect of antibiotic-loaded bone cement (ALBC) on inflammatory factors, and its preventive effect on postoperative infections in unicompartmental knee arthroplasty (UKA).

Methods: This prospective randomized controlled trial enrolled 104 osteoarthritis patients undergoing UKA, randomly assigned to the non-ALBC group (n = 52, bone cement without antibiotics) and ALBC group (ALBC with 1.0 g vancomycin hydrochloride, n = 52). Primary outcomes were postoperative inflammatory markers (CRP, ESR, TNF-α, IL-6); secondary outcomes included infection rate and HSS score. Independent-samples t-tests were used for continuous variables, χ² test for categorical variables (infection rate, efficacy), and repeated measures analysis of variance for intra-group longitudinal comparisons.

Results: The ALBC group demonstrated lower inflammatory markers at postoperative day 7 and at 3 months [CRP (3.52 ± 0.81 vs 6.92 ± 1.17, Cohen's d = 3.379), ESR (16.29 ± 2.31 vs 20.19 ± 4.05, Cohen's d = 1.183), TNF-α (29.71 ± 4.03 vs 36.25 ± 5.17, Cohen's d = 1.411), and IL-6 (17.05 ± 3.72 vs 22.05 ± 4.38, Cohen's d = 1.230)] (all p < 0.001), and also showed superior clinical outcomes, with lower postoperative infection rate (p = 0.016), higher HSS score (p < 0.001), and better overall clinical efficacy (p = 0.010) than the non-ALBC group.

Conclusion: The application of ALBC in UKA was associated with reduced postoperative inflammatory markers such as IL-6 and a lower incidence of postoperative infection. These findings suggest that ALBC may play a beneficial role in postoperative recovery and joint function rehabilitation.

查看原文本刊更多论文

载抗生素骨水泥在单室膝关节置换术中的应用：抑制IL-6水平，降低术后感染率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunopharmacology and Immunotoxicology 医学-毒理学

CiteScore

5.40

自引率

0.00%

发文量

133

审稿时长

4-8 weeks

期刊介绍： The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal. The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome. With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more. Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).